Subtype
Glioma
CI-CAN-00000935Explore in graph →
Non-malignant788 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000935Explore in graph →
Clinical trials
2,806 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03746080 | Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma | completed | Phase 2 | 21 | Lawrence D RechtOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT05045027 | Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma | active not recruiting | Early Phase 1 | 36 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT03107780 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | terminated | Phase 1 | 32 | National Cancer Institute (NCI)NIH | 1 | Nov 13, 2025 | clinicaltrials |
| NCT04657146 | Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma(LAMB-G) | suspended | — | 40 | Duke UniversityOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT04209790 | Neoadjuvant Chemoradiation for Resectable Glioblastoma(NeoGlio) | terminated | Phase 2 | 2 | Geisinger ClinicOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT06090903 | Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma | recruiting | N/A | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05717153 | Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma | recruiting | Early Phase 1 | 18 | Mayo ClinicOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT02162732 | Molecular-Guided Therapy for Childhood Cancer | completed | N/A | 186 | Giselle ShollerOTHER | 2 | Nov 3, 2025 | clinicaltrials |
| NCT04319276 | Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma | active not recruiting | Phase 1 | 26 | Medical College of WisconsinOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)(BRAVO) | terminated | Phase 1 | 11 | University of FloridaOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT03452774 | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | recruiting | — | 50,000 | Massive Bio, Inc.INDUSTRY | 2 | Oct 28, 2025 | clinicaltrials |
| NCT04424966 | Infigratinib in Recurrent High-Grade Glioma Patients | terminated | Early Phase 1 | 7 | Nader SanaiOTHER | 1 | Oct 24, 2025 | clinicaltrials |
| NCT06455605 | D2C7-IT + 2141-V11 Combination Post-resection in rGBM | recruiting | Phase 1 | 46 | Darell BignerOTHER | 1 | Oct 23, 2025 | clinicaltrials |
| NCT04826393 | ASP8374 + Cemiplimab in Recurrent Glioma | completed | Phase 1 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT05341947 | Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | Jeremy Rudnick, M.DOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04373785 | NG101m Adjuvant Therapy in Glioblastoma Patients | not yet recruiting | Phase 1 / Phase 2 | 52 | NeuGATE TheranosticsINDUSTRY | 1 | Oct 21, 2025 | clinicaltrials |
| NCT01991977 | 18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy | completed | Phase 2 | 91 | Mayo ClinicOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT03101813 | International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository | recruiting | — | 1,500 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT02685605 | Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme(INTRAGO-II) | active not recruiting | Phase 3 | 314 | Universitätsmedizin MannheimOTHER | 8 | Oct 14, 2025 | clinicaltrials |
| NCT04982926 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | terminated | Phase 1 | 29 | Taiho Oncology, Inc.INDUSTRY | 2 | Oct 14, 2025 | clinicaltrials |
| NCT00807027 | Clinical Trial to Assess the Efficacy and Safety of 'Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea | completed | Phase 3 | 180 | GC Cell CorporationINDUSTRY | 1 | Oct 10, 2025 | clinicaltrials |
| NCT00870129 | Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors | recruiting | N/A | 135 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | terminated | Early Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT06059690 | Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells | recruiting | Phase 1 / Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT03426891 | Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | completed | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05734560 | D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients | recruiting | Phase 1 / Phase 2 | 50 | Darell BignerOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT02062827 | Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma(M032-HSV-1) | active not recruiting | Phase 1 | 29 | University of Alabama at BirminghamOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT05974410 | Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients | available | — | — | AVM Biotechnology IncINDUSTRY | 0 | Oct 2, 2025 | clinicaltrials |
| NCT06439420 | CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial(CBT-I in PBT) | completed | Phase 2 | 70 | Virginia Commonwealth UniversityOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07198256 | AI-assisted Diagnosis of Malignant Brain Tumors | recruiting | — | 3,000 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07197086 | Clinical and Treatment Determinant of Prognosis in Glioblastoma | not yet recruiting | — | 50 | Assiut UniversityOTHER | 0 | Sep 29, 2025 | clinicaltrials |
| NCT05310448 | Tumor Treating Fields for the Treatment of Brainstem Gliomas | recruiting | N/A | 10 | Emory UniversityOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT07193654 | Stupp Treatment With Intrathecal Injection of Thiotepa for Glioblastoma With Advanced Spread | recruiting | Phase 2 | 38 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05608395 | 11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)(GlioMET) | completed | Phase 2 | 33 | Masaryk Memorial Cancer InstituteOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05532397 | Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma | recruiting | N/A | 10 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT04772456 | Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas | recruiting | Phase 1 | 5 | University of Maryland, BaltimoreOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT05157594 | hPG80 (Circulating Progastrin) as a Blood Biomarker for High-grade Glial Tumors(PROGLIO) | completed | — | 30 | Centre Jean PerrinOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT02864888 | Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma(DBSG) | not yet recruiting | Phase 3 | 30 | Burzynski Research InstituteOTHER | 0 | Sep 19, 2025 | clinicaltrials |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | terminated | Phase 1 | 75 | Ikena OncologyINDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06776250 | Study of How Safe and Effective Tarlatamab is in Brain Cancers | recruiting | Phase 2 | 44 | University Health Network, TorontoOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06835803 | Enhanced Local Intensified Radiation Therapy in Elderly Glioblastoma: A Phase 2 Hybrid Randomized Trial(ELITE-GBM) | recruiting | Phase 2 | 56 | Brigham and Women's HospitalOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07179328 | Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy | recruiting | Phase 1 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT02742883 | A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) | suspended | Phase 2 | 1 | Burzynski Research InstituteOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT02887040 | Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma(DIPG) | not yet recruiting | Phase 3 | 92 | Burzynski Research InstituteOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT04802447 | SurVaxM Expanded Access Protocol(EAP) | no longer available | — | — | Roswell Park Cancer InstituteOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT06831461 | Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors(PRIDE) | recruiting | N/A | 156 | Tata Memorial CentreOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT07141732 | Combined Treatment of Patients With Newly Diagnosed Glioblastoma Using the Xoft® Axxent® Electronic Brachytherapy (eBx®) System for Intraoperative Balloon Electronic Brachytherapy | recruiting | Phase 1 | 15 | Joint Stock Company European Medical CentreOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT01811121 | MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS(RESECT) | completed | Phase 3 | 170 | Hospices Civils de LyonOTHER | 1 | Sep 15, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Nov 14, 2025source: clinicaltrials